1-3 of 3
Emily Knight
Close
Sort by
Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Lisa Sproat, MD MSW, Jeanne Palmer, MD, James L. Slack, MD, Devinder Singh, MD, Eileen Gebhart, MSN, RN, ANP-BC, Emily Knight, RN, Shahrukh K. Hashmi, MD, Ryan A Wilcox, MD PhD, James M Bogenberger, PhD, Ruben A. Mesa, Aref Al-Kali, MD
Journal: Blood
Blood (2015) 126 (23): 1347.
https://doi.org/10.1182/blood.V126.23.1347.1347
Published: 2015
Journal Articles

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Veena Fauble, MD, Robyn M. Emanuel, MD, MPH, Holly Lynn Geyer, MD, Amylou Constance Dueck, PhD, Nicolaus Kroeger, MD, Bart L Scott, MD, Aaron T Gerds, MD, MS, Uday R Popat, MD, Sergio A Giralt, MD, Vikas Gupta, MD, FRCP, FRCPath, David Ross, MBBS, PhD, Emily Knight, Ana Kerguelen Fuentes, MD, Christen Lykkegaard Andersen, MD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD, PhD, Peter Johansson, MD, PhD, Bjorn Andreasson, MD, Federico Sackmann, Jean-Loup Demory, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Jan J. Michiels, PhD, Deepti H Radia, MD FRCPath MSc Med Ed, Michael Boxer, MD, Ruben A. Mesa, MD
Journal: Blood
Blood (2013) 122 (21): 4090.
https://doi.org/10.1182/blood.V122.21.4090.4090
Published: 2013
Journal Articles

Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval

Holly Lynn Geyer, MD, Emily Knight, Keith Cannon, MD, Kathryn Barr, N. P., Raoul Tibes, MD, PhD, John Camoriano, MD, Pierre Noel, MD, Ruben A. Mesa
Journal: Blood
Blood (2012) 120 (21): 5061.
https://doi.org/10.1182/blood.V120.21.5061.5061
Published: 2012